1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events

5. SWOT Analysis

6. Epidemiology and Market Forecast Methodology

7. Neuroblastoma: Market Overview (%) at a Glance

7.1. Market Size of Neuroblastoma by Therapies in 2020

7.2. Market Size of Neuroblastoma by Therapies in 2032

8. Disease Background and Overview

8.1. Introduction

8.2. Causes

8.3. Pathophysiology

8.4. Symptoms

8.5. Risk Factor

8.6. Diagnosis

9. Current Treatment and Medical Practices

9.1. Treatment Guidelines

9.2. Treatment Algorithm

10. Epidemiology and Patient Population

10.1. Key Findings

10.2. Assumptions and Rationale of Neuroblastoma in the 7MM

10.3. 7MM Incident cases of Neuroblastoma (2020-2032)

10.4. The United States

10.4.1. Incident cases of Neuroblastoma (2020-2032)

10.4.2. Age-specific Incident Cases of Neuroblastoma (2020-2032)

10.4.3. Gender-specific Incident Cases of Neuroblastoma (2020-2032)

10.4.4. Incident Patient Population of Neuroblastoma by Risk Groups (2020-2032)

10.5. EU4 (Germany, France, Italy, and Spain) and the UK)

10.5.1. Incident cases of Neuroblastoma (2020-2032)

10.5.2. Age-specific Incident Cases of Neuroblastoma (2020-2032)

10.5.3. Gender-specific Incident Cases of Neuroblastoma (2020-2032)

10.5.4. Incident Patient Population of Neuroblastoma by Risk Groups (2020-2032)

10.6. Japan

10.6.1. Incident cases of Neuroblastoma (2020-2032)

10.6.2. Age-specific Incident Cases of Neuroblastoma (2020-2032)

10.6.3. Gender-specific Incident Cases of Neuroblastoma (2020-2032)

10.6.4. Incident Patient Population of Neuroblastoma by Risk Groups (2020-2032)

11. Patient Journey

12. Key Endpoint of Clinical Trials

13. Marketed Therapies

13.1. Key Cross Competition

13.2.Qarziba: EUSA Pharma

13.2.1. Product Description

13.2.2. Regulatory Milestones

13.2.3. Other Developmental Activities

13.2.4. Safety and efficacy

13.2.5. Product Profile

13.3.Unituxin: United Therapeutics

13.3.1. Product Description

13.3.2. Regulatory Milestones

13.3.3. Other Developmental Activities

13.3.4. Safety and efficacy

13.3.5. Product Profile

13.4 .Danyelza: Y-mabs therapeutics

13.4.1. Product Description

13.4.2. Regulatory Milestones

13.4.3. Other Developmental Activities

13.4.4. Safety and efficacy

13.4.5. Product Profile

14. Emerging Therapies

14.1. Key Cross Competition

14.2.Omburtamab: Y-mabs therapeutics

14.2.1. Product Description

14.2.2. Other Developmental Activities

14.2.3. Clinical Development

14.2.4. Safety and efficacy

14.2.5. Product Profile

14.3. SARTATE: Clarity Pharmaceuticals

14.3.1. Product Description

14.3.2. Other Developmental Activities

14.3.3. Clinical Development

14.3.4. Safety and efficacy

14.3.5. Product Profile

14.4. Eflornithine: K C Pharmaceuticals

14.4.1. Product Description

14.4.2. Other Developmental Activities

14.4.3. Clinical Development

14.4.4. Safety and efficacy

14.4.5. Product Profile

List to be continued in the report…

15. Low-Grade Serous Ovarian Carcinoma: Market Size of 7MM

15.1. Key Findings

15.2. Market Outlook: 7MM

15.3. Attribute Analysis

15.4. Key Market Forecast Assumptions

15.5. Total Market Size of Neuroblastoma in the 7MM (2020-2032)

15.6. Market size of Neuroblastoma by Therapies in the 7MM (2020-2032)

15.7. The United States Market Size

15.7.1. Total Market Size of Neuroblastoma in the United States (2020-2032)

15.7.2. Market Size of Neuroblastoma by Therapies in the United States (2020-2032)

15.8. EU4 (Germany, France, Italy, and Spain), and the UK Market Size

15.8.1. Total Market Size of Neuroblastoma in EU4 and the UK (2020-2032)

15.8.2. Market Size of Neuroblastoma by Therapies in EU4 and the UK (2020-2032)

15.9. Japan

15.9.1. Total Market Size of Neuroblastoma in Japan (2020-2032)

15.9.2. Market Size of Neuroblastoma by Therapies in Japan (2020-2032)

16. Market Access and Reimbursement

17. Unmet Needs

18. Appendix

18.1. Bibliography

18.2. Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight